Medicines Co. Stock
-
Your prediction
Pros and Cons of Medicines Co. in the next few years
Pros
Cons
Performance of Medicines Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | -0.780% | -0.283% | -5.120% | 0.643% | 0.643% | -11.626% | -8.658% |
| Opko Health Inc. | 3.340% | -1.365% | -5.262% | -24.046% | -24.046% | -5.584% | -68.540% |
| Amicus Therapeutics Inc. | -0.830% | 0.833% | 41.520% | 32.240% | 32.240% | 8.520% | -33.880% |
Comments
News
Why Praxis Precision Medicines Stock Popped Today
Shares of Praxis Precision Medicines (NASDAQ: PRAX) leaped on Monday after the clinical-stage biopharmaceutical company received a Breakthrough Therapy Designation (BTD) for its experimental tremor
Meet the Biotech Stock That Just Jumped 251% Higher
Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks. In this wonky industry, encouraging results from a clinical trial can
Royalty Pharma (RPRX) Q2 Receipts Up 20%
Royalty Pharma Plc (NASDAQ:RPRX), a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts—its


